Ligand Pharmaceuticals to Acquire XOMA Royalty Corporation: Investor-Focused Analysis
Ligand Pharmaceuticals to Acquire XOMA Royalty Corporation for \$739 Million: Major Expansion of Royalty Portfolio
Key Highlights of the Acquisition
- Definitive Agreement: Ligand Pharmaceuticals (Nasdaq: LGND) will acquire XOMA Royalty Corporation (Nasdaq: XOMA) for \$39.00 per share in cash, representing a total equity value of approximately \$739 million and a 14% premium over XOMA Royalty’s 30-day VWAP before announcement.
- Portfolio Expansion: The transaction will expand Ligand’s royalty portfolio to over 200 assets, adding seven new commercial products and nearly doubling the number of Phase 2 and 3 assets.
- Immediate Financial Impact: The acquisition is expected to be immediately accretive to Ligand’s adjusted EPS. Ligand has updated its 2026 adjusted EPS guidance to \$8.50-\$9.50 (up from \$8.00-\$9.00), with expectations of \$1.50 per share accretion to adjusted EPS in 2027.
- Contingent Value Right (CVR): XOMA Royalty stockholders will also receive a non-transferable CVR per share, entitling holders to 75% of net proceeds from certain pending litigation with Janssen Biotech (now Johnson & Johnson Innovative Medicine).
- Board & Shareholder Support: The boards of both companies have unanimously approved the transaction. BVF Partners, holding 21% of XOMA Royalty common stock (44% with Series X Preferred conversion), and XOMA Royalty directors/officers have entered voting agreements.
- Closing Timeline: The deal is expected to close in Q3 2026, pending customary conditions, XOMA Royalty stockholder approval, and regulatory clearances.
- Revenue Guidance Update: Ligand now anticipates 2026 revenues of \$270-\$310 million, up from previous guidance of \$245-\$285 million. Royalty revenues are projected at \$225-\$250 million (previously \$200-\$225 million).
- Strategic Rationale: Ligand will strengthen its leadership as a biopharma royalty aggregator, diversify its asset base across therapeutic areas (ophthalmology, oncology, CNS, rare diseases), and broaden patient access to innovative treatments.
- Litigation Optionality: The CVR provides exposure to potential proceeds from ongoing litigation concerning TREMFYA® commercialization, which could provide additional upside for XOMA Royalty shareholders.
- Advisors: Stifel and Citi are advising Ligand, while Leerink Partners and H.C. Wainwright & Co. are advising XOMA Royalty. Legal counsel includes Paul Hastings LLP for Ligand and Gibson, Dunn & Crutcher LLP for XOMA Royalty.
Transaction Terms and Shareholder Considerations
- Common Stock Offer: All outstanding XOMA Royalty common shares will be acquired for \$39.00 per share in cash.
- Preferred Shares: Series X Convertible Preferred Stock will convert to common stock at a fixed price prior to closing; Series A and B Preferred Stock will be redeemed.
- Funding: Ligand will fund the acquisition through cash on hand and existing credit facilities.
- CVR Opportunity: Shareholders receive a CVR per share with potential future payout tied to litigation outcome, representing material optionality beyond the cash consideration.
- Voting Agreements: Major shareholders and management have committed to support the deal, reducing execution risk.
- Regulatory & Shareholder Approval: The deal is contingent on approvals. Investors should monitor for potential delays or competing offers, both of which could impact share prices.
Portfolio Details and Strategic Synergies
Ligand’s expanded portfolio will now include commercial, clinical, and preclinical assets, highlighted by key products such as Roche’s VABYSMO® (faricimab-svoa), Day One Pharmaceuticals’ OJEMDA™ (tovorafenib), Zevra Therapeutics’ MIPLYFFA™ (arimoclomol), and 14 late-stage programs including Takeda’s mezagitamab, osavampator, volixibat, and OHB-607. This breadth across development stages and modalities is expected to deliver long-term compounding growth and broaden Ligand’s exposure to various therapeutic areas.
Financial Implications and Guidance
- EPS Accretion: Immediate accretion to adjusted EPS in 2026; \$1.50 per share accretion expected in 2027.
- Revenue Growth: Upward revision of 2026 revenue and royalty guidance, indicating anticipated strong financial performance post-acquisition.
- Stable Asset Mix: Guidance for Captisol® and contract revenues remain unchanged, suggesting stability in the underlying business.
Risks and Forward-Looking Statements
Investors should be aware of risks related to the completion of the acquisition (regulatory, shareholder approval, potential competing offers), integration challenges, realization of expected synergies, litigation outcomes, and uncertainties in royalty and milestone payments. Additional risks include market volatility, regulatory changes, and dependency on collaborative partners for revenue streams. These factors could materially affect the value proposition and share price of both Ligand and XOMA Royalty.
Additional Information
XOMA Royalty will file proxy materials with the SEC for shareholder approval. Investors are strongly encouraged to review these documents before making any voting decisions. No offer or solicitation is being made in this release; the acquisition is subject to legal and regulatory requirements.
Contact Information
Disclaimer
This article contains forward-looking statements based on current expectations and judgments. Actual results may differ materially due to risks and uncertainties including, but not limited to, regulatory approvals, integration challenges, litigation outcomes, and market conditions. Investors should review all SEC filings and consult with their financial advisers before making investment decisions. This article is for informational purposes only and does not constitute a solicitation or offer to buy or sell securities.
View XOMA Royalty Corp Historical chart here
